Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.01
RDNT's Cash-to-Debt is ranked lower than
100% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.32 vs. RDNT: 0.01 )
Ranked among companies with meaningful Cash-to-Debt only.
RDNT' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0 Max: N/A
Current: 0.01
Equity-to-Asset 0.06
RDNT's Equity-to-Asset is ranked lower than
92% of the 216 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.60 vs. RDNT: 0.06 )
Ranked among companies with meaningful Equity-to-Asset only.
RDNT' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.85  Med: -0.16 Max: 0.06
Current: 0.06
-0.85
0.06
Interest Coverage 0.98
RDNT's Interest Coverage is ranked lower than
95% of the 153 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.14 vs. RDNT: 0.98 )
Ranked among companies with meaningful Interest Coverage only.
RDNT' s Interest Coverage Range Over the Past 10 Years
Min: 0.48  Med: 0.88 Max: 1.25
Current: 0.98
0.48
1.25
Piotroski F-Score: 5
Altman Z-Score: 1.36
Beneish M-Score: -3.43
WACC vs ROIC
6.70%
3.92%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 4.71
RDNT's Operating Margin % is ranked higher than
56% of the 221 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.53 vs. RDNT: 4.71 )
Ranked among companies with meaningful Operating Margin % only.
RDNT' s Operating Margin % Range Over the Past 10 Years
Min: 4.35  Med: 6.6 Max: 8.66
Current: 4.71
4.35
8.66
Net Margin % 0.86
RDNT's Net Margin % is ranked higher than
52% of the 220 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.48 vs. RDNT: 0.86 )
Ranked among companies with meaningful Net Margin % only.
RDNT' s Net Margin % Range Over the Past 10 Years
Min: -4.26  Med: 0.25 Max: 9.25
Current: 0.86
-4.26
9.25
ROE % 19.21
RDNT's ROE % is ranked higher than
87% of the 214 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.64 vs. RDNT: 19.21 )
Ranked among companies with meaningful ROE % only.
RDNT' s ROE % Range Over the Past 10 Years
Min: 17.84  Med: 40.64 Max: 52.1
Current: 19.21
17.84
52.1
ROA % 0.92
RDNT's ROA % is ranked higher than
58% of the 237 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.39 vs. RDNT: 0.92 )
Ranked among companies with meaningful ROA % only.
RDNT' s ROA % Range Over the Past 10 Years
Min: -6.42  Med: 0.25 Max: 9
Current: 0.92
-6.42
9
ROC (Joel Greenblatt) % 16.43
RDNT's ROC (Joel Greenblatt) % is ranked higher than
61% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.64 vs. RDNT: 16.43 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RDNT' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 14.13  Med: 17.94 Max: 25.77
Current: 16.43
14.13
25.77
3-Year Revenue Growth Rate 2.40
RDNT's 3-Year Revenue Growth Rate is ranked lower than
61% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 5.40 vs. RDNT: 2.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
RDNT' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 2.4  Med: 8.6 Max: 25.5
Current: 2.4
2.4
25.5
3-Year EBITDA Growth Rate -1.80
RDNT's 3-Year EBITDA Growth Rate is ranked lower than
61% of the 144 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.60 vs. RDNT: -1.80 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RDNT' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -43  Med: 6.6 Max: 174
Current: -1.8
-43
174
3-Year EPS without NRI Growth Rate 44.20
RDNT's 3-Year EPS without NRI Growth Rate is ranked higher than
90% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.80 vs. RDNT: 44.20 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
RDNT' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -51.8  Med: -14.2 Max: 44.2
Current: 44.2
-51.8
44.2
GuruFocus has detected 6 Warning Signs with RadNet Inc $RDNT.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RDNT's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621491    SIC: 8071
Compare:NAS:OXFD, NAS:SRDX, NYSE:NVTA, NAS:PACB, NAS:ONVO, NAS:QTNT, NYSE:ENZ, NAS:MGEN, OTCPK:EPGNF, OTCPK:CLIFF, AMEX:SENS, NAS:NTRA, NYSE:ARA, NAS:LNTH, NAS:AIQ, NAS:TRIB, NAS:PMD, NAS:FLGT, OTCPK:CBIS, NAS:CTSO » details
Traded in other countries:PQIA.Germany,
Headquarter Location:USA
RadNet Inc is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, and among others.

RadNet Inc is incorporated in Delaware and has been in business since 1985. The Company provides freestanding, fixed-site outpatient diagnostic imaging services in the United States based on number of locations and annual imaging revenue. At December 31, 2012, it operated directly or indirectly through joint ventures, 250 centers located in California, Maryland, Florida, Delaware, New Jersey, Rhode Island and New York. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. Diagnostic imaging involves the use of non-invasive procedures to generate representations of internal anatomy and function that can be recorded on film or digitized for display on a video monitor. Diagnostic imaging procedures facilitate the early diagnosis and treatment of diseases and disorders and may reduce unnecessary invasive procedures, often minimizing the cost and amount of care for patients. Diagnostic imaging procedures include MRI, CT, PET, nuclear medicine, ultrasound, mammography, X-ray and fluoroscopy. While X-ray remains the commonly performed diagnostic imaging procedure, the growing and higher margin procedures are MRI, CT and PET. The rapid growth in PET scans is attributable to the increasing recognition of the efficacy of PET scans in the diagnosis and monitoring of cancer. The number of MRI and CT scans performed annual in the United States continues to grow due to their wider acceptance by physicians and payors, an increasing number of applications for their use and a general increase in demand due to the aging population. The Company's sales and marketing team employs a multi-pronged approach to marketing, including physician, payor and sports marketing programs. The market for diagnostic imaging services is competitive. The Company competes locally with groups of radiologists, established hospitals, clinics and other independent organizations that own and operate imaging equipment. Its competitors include Alliance Healthcare Services, Inc., Diagnostic Imaging Group and several smaller regional competitors.

Ratios

vs
industry
vs
history
PE Ratio 48.13
RDNT's PE Ratio is ranked lower than
66% of the 107 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.35 vs. RDNT: 48.13 )
Ranked among companies with meaningful PE Ratio only.
RDNT' s PE Ratio Range Over the Past 10 Years
Min: 1.44  Med: 22.14 Max: 961
Current: 48.13
1.44
961
PE Ratio without NRI 48.13
RDNT's PE Ratio without NRI is ranked lower than
65% of the 109 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.61 vs. RDNT: 48.13 )
Ranked among companies with meaningful PE Ratio without NRI only.
RDNT' s PE Ratio without NRI Range Over the Past 10 Years
Min: 1.44  Med: 22.14 Max: 961
Current: 48.13
1.44
961
PB Ratio 7.32
RDNT's PB Ratio is ranked lower than
78% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.75 vs. RDNT: 7.32 )
Ranked among companies with meaningful PB Ratio only.
RDNT' s PB Ratio Range Over the Past 10 Years
Min: 5.09  Med: 9.54 Max: 715.38
Current: 7.32
5.09
715.38
PS Ratio 0.40
RDNT's PS Ratio is ranked higher than
95% of the 214 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.61 vs. RDNT: 0.40 )
Ranked among companies with meaningful PS Ratio only.
RDNT' s PS Ratio Range Over the Past 10 Years
Min: 0.07  Med: 0.27 Max: 1.08
Current: 0.4
0.07
1.08
Price-to-Free-Cash-Flow 12.07
RDNT's Price-to-Free-Cash-Flow is ranked higher than
89% of the 79 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 24.66 vs. RDNT: 12.07 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
RDNT' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 1.59  Med: 11.37 Max: 185
Current: 12.07
1.59
185
Price-to-Operating-Cash-Flow 3.53
RDNT's Price-to-Operating-Cash-Flow is ranked higher than
98% of the 91 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.27 vs. RDNT: 3.53 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
RDNT' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 0.56  Med: 2.76 Max: 25.84
Current: 3.53
0.56
25.84
EV-to-EBIT 17.53
RDNT's EV-to-EBIT is ranked higher than
71% of the 115 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 26.02 vs. RDNT: 17.53 )
Ranked among companies with meaningful EV-to-EBIT only.
RDNT' s EV-to-EBIT Range Over the Past 10 Years
Min: 9.3  Med: 17.7 Max: 44.7
Current: 17.53
9.3
44.7
EV-to-EBITDA 8.05
RDNT's EV-to-EBITDA is ranked higher than
88% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.53 vs. RDNT: 8.05 )
Ranked among companies with meaningful EV-to-EBITDA only.
RDNT' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.1  Med: 7.3 Max: 16.3
Current: 8.05
5.1
16.3
Shiller PE Ratio 77.77
RDNT's Shiller PE Ratio is ranked lower than
81% of the 31 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 46.11 vs. RDNT: 77.77 )
Ranked among companies with meaningful Shiller PE Ratio only.
RDNT' s Shiller PE Ratio Range Over the Past 10 Years
Min: 53.5  Med: 130.8 Max: 763
Current: 77.77
53.5
763
Current Ratio 1.31
RDNT's Current Ratio is ranked lower than
81% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.72 vs. RDNT: 1.31 )
Ranked among companies with meaningful Current Ratio only.
RDNT' s Current Ratio Range Over the Past 10 Years
Min: 0.15  Med: 1.1 Max: 1.9
Current: 1.31
0.15
1.9
Quick Ratio 1.31
RDNT's Quick Ratio is ranked lower than
73% of the 236 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. RDNT: 1.31 )
Ranked among companies with meaningful Quick Ratio only.
RDNT' s Quick Ratio Range Over the Past 10 Years
Min: 0.15  Med: 1.1 Max: 1.9
Current: 1.31
0.15
1.9
Days Sales Outstanding 68.97
RDNT's Days Sales Outstanding is ranked lower than
58% of the 189 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.14 vs. RDNT: 68.97 )
Ranked among companies with meaningful Days Sales Outstanding only.
RDNT' s Days Sales Outstanding Range Over the Past 10 Years
Min: 61.13  Med: 71.6 Max: 80.12
Current: 68.97
61.13
80.12
Days Payable 19.06
RDNT's Days Payable is ranked lower than
86% of the 184 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 58.94 vs. RDNT: 19.06 )
Ranked among companies with meaningful Days Payable only.
RDNT' s Days Payable Range Over the Past 10 Years
Min: 14.67  Med: 23.65 Max: 28.38
Current: 19.06
14.67
28.38

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -5.10
RDNT's 3-Year Average Share Buyback Ratio is ranked higher than
54% of the 151 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.50 vs. RDNT: -5.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RDNT' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -20.1  Med: -2.1 Max: 0.8
Current: -5.1
-20.1
0.8

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 1.47
RDNT's Price-to-Median-PS-Value is ranked lower than
75% of the 200 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. RDNT: 1.47 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RDNT' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24  Med: 0.82 Max: 3.6
Current: 1.47
0.24
3.6
Earnings Yield (Greenblatt) % 5.70
RDNT's Earnings Yield (Greenblatt) % is ranked higher than
86% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.52 vs. RDNT: 5.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RDNT' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.2  Med: 5.7 Max: 10.8
Current: 5.7
2.2
10.8
Forward Rate of Return (Yacktman) % -5.98
RDNT's Forward Rate of Return (Yacktman) % is ranked lower than
85% of the 65 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 6.56 vs. RDNT: -5.98 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
RDNT' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -13.1  Med: 3.6 Max: 23.9
Current: -5.98
-13.1
23.9

More Statistics

Revenue (TTM) (Mil) $897.16
EPS (TTM) $ 0.16
Beta1.49
Short Percentage of Float1.01%
52-Week Range $5.02 - 7.98
Shares Outstanding (Mil)47.22
» More Articles for RDNT

Headlines

Articles On GuruFocus.com
RadNet, Inc. Acquires Equity Stake in Medic Vision Jun 20 2017 
RadNet, Inc. to Present at the Jefferies 2017 Healthcare Conference on June 9, 2017 Jun 07 2017 
RadNet, Inc. Announces Date of its First Quarter 2017 Financial Results Conference Call Apr 28 2017 
Shin Imaging Center Implements eRAD Platform Apr 24 2017 
Adams Diagnostic Innovates with eRAD Technology Apr 21 2017 
Advanced Diagnostic Imaging Center Deploys eRAD Platform Apr 20 2017 
RadNet Announces Formation of Two Los Angeles-Area Joint Ventures With Cedars-Sinai Apr 03 2017 
Doral Financial Corp (DRL) Skyrockets with Unusual Market Activity, RadNet Inc (RDNT) Soars on Resul May 12 2014 
Weekly 3-Year Lows Highlight: FWM, FST, LAND, RDNT Jan 13 2014 
RadNet Inc. Reports Operating Results (10-K) Mar 11 2011 

More From Other Websites
RadNet, Inc. Acquires Equity Stake in Medic Vision Jun 20 2017
ETFs with exposure to RadNet, Inc. : June 8, 2017 Jun 08 2017
RadNet, Inc. to Present at the Jefferies 2017 Healthcare Conference on June 9, 2017 Jun 07 2017
RadNet, Inc. :RDNT-US: Earnings Analysis: Q1, 2017 By the Numbers : June 6, 2017 Jun 06 2017
Edited Transcript of RDNT earnings conference call or presentation 10-May-17 2:30pm GMT May 16 2017
Investor Network: RadNet, Inc. to Host Earnings Call May 10 2017
RadNet reports 1Q loss May 10 2017
RadNet Reports First Quarter Financial Results and Reaffirms 2017 Guidance Ranges May 10 2017
RadNet, Inc. Announces Date of its First Quarter 2017 Financial Results Conference Call Apr 28 2017
Shin Imaging Center Implements eRAD Platform Apr 24 2017
Adams Diagnostic Innovates with eRAD Technology Apr 21 2017
Advanced Diagnostic Imaging Center Deploys eRAD Platform Apr 20 2017
ETFs with exposure to RadNet, Inc. : April 5, 2017 Apr 05 2017
RadNet Announces Formation of Two Los Angeles-Area Joint Ventures With Cedars-Sinai Apr 03 2017
RadNet, Inc. :RDNT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Mar 21 2017
Edited Transcript of RDNT earnings conference call or presentation 14-Mar-17 2:30pm GMT Mar 14 2017
RadNet posts 4Q profit Mar 14 2017
RadNet Announces Amendment to First Lien Credit Facilities Feb 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}